These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon. Drugs R D; 2006; 7(3):197-201. PubMed ID: 16752945 [TBL] [Abstract][Full Text] [Related]
3. Immunotherapy in prostate cancer: emerging strategies against a formidable foe. Bilusic M; Heery C; Madan RA Vaccine; 2011 Sep; 29(38):6485-97. PubMed ID: 21741424 [TBL] [Abstract][Full Text] [Related]
4. Sipuleucel-T for prostate cancer: the immunotherapy era has commenced. Buonerba C; Ferro M; Di Lorenzo G Expert Rev Anticancer Ther; 2011 Jan; 11(1):25-8. PubMed ID: 21166508 [TBL] [Abstract][Full Text] [Related]
5. Update on prostate cancer vaccines. Drake CG Cancer J; 2011; 17(5):294-9. PubMed ID: 21952278 [TBL] [Abstract][Full Text] [Related]
6. Immunotherapy for the treatment of prostate cancer. Di Lorenzo G; Buonerba C; Kantoff PW Nat Rev Clin Oncol; 2011 May; 8(9):551-61. PubMed ID: 21606971 [TBL] [Abstract][Full Text] [Related]
7. Current status of immunological approaches for the treatment of prostate cancer. Drake CG; Antonarakis ES Curr Opin Urol; 2012 May; 22(3):197-202. PubMed ID: 22328018 [TBL] [Abstract][Full Text] [Related]
8. Immunotherapy of Prostate Cancer: Facts and Hopes. Bilusic M; Madan RA; Gulley JL Clin Cancer Res; 2017 Nov; 23(22):6764-6770. PubMed ID: 28663235 [TBL] [Abstract][Full Text] [Related]
9. Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy. Antonarakis ES; Drake CG Curr Opin Oncol; 2012 May; 24(3):258-65. PubMed ID: 22410456 [TBL] [Abstract][Full Text] [Related]
10. Recent advances in immunotherapy for the treatment of prostate cancer. Sonpavde G; Agarwal N; Choueiri TK; Kantoff PW Expert Opin Biol Ther; 2011 Aug; 11(8):997-1009. PubMed ID: 21675925 [TBL] [Abstract][Full Text] [Related]
11. Prostate cancer vaccines: current status and future potential. Doehn C; Böhmer T; Kausch I; Sommerauer M; Jocham D BioDrugs; 2008; 22(2):71-84. PubMed ID: 18345705 [TBL] [Abstract][Full Text] [Related]
12. Development of novel immune interventions for prostate cancer. Agarwal N; Padmanabh S; Vogelzang NJ Clin Genitourin Cancer; 2012 Jun; 10(2):84-92. PubMed ID: 22409862 [TBL] [Abstract][Full Text] [Related]
13. Clinical development of immunotherapy for prostate cancer. Noguchi M; Koga N; Igawa T; Itoh K Int J Urol; 2017 Sep; 24(9):675-680. PubMed ID: 28636142 [TBL] [Abstract][Full Text] [Related]
14. Therapeutic prostate cancer vaccines: a review of the latest developments. Mohebtash M; Madan RA; Gulley JL; Arlen PM Curr Opin Investig Drugs; 2008 Dec; 9(12):1296-301. PubMed ID: 19037836 [TBL] [Abstract][Full Text] [Related]
15. Advances in cancer vaccines for immunotherapy of prostate cancer. Jin T; Zhou C; Zhao L; Dong X; Zhou F Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Jan; 48(1):148-156. PubMed ID: 36935188 [TBL] [Abstract][Full Text] [Related]
16. New treatments for metastic prostate cancer. Med Lett Drugs Ther; 2010 Sep; 52(1346):69-70. PubMed ID: 20814400 [TBL] [Abstract][Full Text] [Related]
17. From bench to bedside: immunotherapy for prostate cancer. Tse BW; Jovanovic L; Nelson CC; de Souza P; Power CA; Russell PJ Biomed Res Int; 2014; 2014():981434. PubMed ID: 25276838 [TBL] [Abstract][Full Text] [Related]
18. Therapeutic vaccines for prostate cancer. Cha E; Fong L Curr Opin Mol Ther; 2010 Feb; 12(1):77-85. PubMed ID: 20140819 [TBL] [Abstract][Full Text] [Related]
19. Preclinical and clinical development of DNA vaccines for prostate cancer. Colluru VT; Johnson LE; Olson BM; McNeel DG Urol Oncol; 2016 Apr; 34(4):193-204. PubMed ID: 24332642 [TBL] [Abstract][Full Text] [Related]
20. The evolving role of immunotherapy in prostate cancer. Gerritsen WR Ann Oncol; 2012 Sep; 23 Suppl 8():viii22-7. PubMed ID: 22918924 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]